The article reports on the motion filed by the U.S. Justice Department in the federal court in Maryland which alleges that drug manufacturer Ranbaxy Laboratories has forged documents related to the quality of its drugs distributed in the U.S. Under the motion, the company is ordered to submit the documents for verification. The investigation over the firm was conducted after Food and Drug Administration (FDA) inspectors discovered inconsistencies in the manufacturing processes and maintenance of data in its facility in India.